New option for people with myelofibrosis in the USA

2 March 2022
us_fda_big

Seattle, USA-based hematology company CTI BioPharma (Nasdaq: CTIC) has won approval from the US Food and Drug Administration for Vonjo (pacritinib) in myelofibrosis.

The rare blood cancer, which affects about 21,000 people in the country, causes scarring of the bone marrow, making it difficult for the body to produce blood cells.

Vonjo is approved for the treatment of certain adults with intermediate or high-risk primary or secondary forms of the disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical